NRAS mutation in melanoma seems to be a prognostic marker of worse prognosis and more aggressive disease, with several studies indicating that OS for patients with NRAS-mutant melanoma is significantly lower compared to those with BRAF-mutant or NRAS/BRAF-wildtype tumor status [12,13]. This evidence concerns the gene NRAS and neoplasm.